List of Excipients in Branded Drug SORAFENIB

Generic Drugs Containing SORAFENIB

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals Inc	sorafenib	0480-5425	HYPROMELLOSE 2910
Teva Pharmaceuticals Inc	sorafenib	0480-5425	MICROCRYSTALLINE CELLULOSE 102
Torrent Pharmaceuticals Limited	sorafenib	13668-682	CELLULOSE, MICROCRYSTALLINE
Torrent Pharmaceuticals Limited	sorafenib	13668-682	CROSCARMELLOSE SODIUM
Torrent Pharmaceuticals Limited	sorafenib	13668-682	FERRIC OXIDE RED
Torrent Pharmaceuticals Limited	sorafenib	13668-682	HYPROMELLOSE
Torrent Pharmaceuticals Limited	sorafenib	13668-682	MAGNESIUM STEARATE

What are the Most Frequently-Used Excipients in SORAFENIB?

# Of NDCs	Excipient
6	CELLULOSE, MICROCRYSTALLINE
6	CROSCARMELLOSE SODIUM
5	FERRIC OXIDE RED
1	FERRIC OXIDE YELLOW
5	HYPROMELLOSE
2	HYPROMELLOSE 2910
6	MAGNESIUM STEARATE

# Sorafenib Excipient Strategy and Commercial Opportunities in Generic and Specialty Formulations

Last updated: August 19, 2026

Sorafenib is an orally administered, poorly water-soluble small molecule marketed originally as Nexavar. Its commercial formulation is a 200 mg film-coated tablet containing sorafenib tosylate, with excipients selected to support powder flow, tablet compression, disintegration, coating performance, and chemical stability. The active ingredient is no longer protected by biologic exclusivity principles, and generic competition has shifted value toward manufacturing reliability, bioequivalence, differentiated dosage forms, supply-chain economics, and specialty delivery technologies.

The strongest excipient opportunities are in solubility enhancement, dissolution control, tablet robustness, taste and swallowability, and alternative oral delivery. Conventional generic tablets remain the lowest-risk route, while amorphous solid dispersions, lipid-based systems, nanosized sorafenib, and modified-release products offer higher technical and regulatory risk.

What excipients are used in sorafenib tablets?

The reference product contains sorafenib tosylate equivalent to 200 mg of sorafenib per tablet. The tablet is film-coated and is administered orally for unresectable hepatocellular carcinoma, advanced renal cell carcinoma, and radioactive iodine-resistant differentiated thyroid carcinoma, subject to the FDA-approved labeling for each indication.[1]

Nexavar tablet excipient profile

Public labeling identifies the following core inactive ingredients:

Formulation component	Reported or typical function
Microcrystalline cellulose	Diluent, compression aid, tablet structure
Croscarmellose sodium	Superdisintegrant
Hypromellose	Binder and film-forming polymer
Sodium lauryl sulfate	Wetting agent and surfactant
Magnesium stearate	Lubricant
Polyethylene glycol	Film-coating plasticizer
Titanium dioxide	Opacifier and coating pigment
Red ferric oxide	Colorant
Purified water or process solvent	Manufacturing medium, removed during drying

Exact excipient grades, quantities, processing conditions, and supplier specifications are generally not disclosed in commercial labeling. These variables can affect dissolution, hardness, friability, moisture uptake, stability, and bioequivalence.

Why is sorafenib an excipient-sensitive drug?

Sorafenib has low aqueous solubility and belongs to the class of orally administered kinase inhibitors for which dissolution and gastrointestinal performance can materially affect exposure. The tosylate salt improves pharmaceutical handling but does not eliminate the formulation challenge. Sorafenib is also highly protein bound and is metabolized primarily through CYP3A4 and UGT1A9, making systemic exposure sensitive to clinical and formulation factors.[1,2]

Key formulation constraints

Constraint	Commercial consequence
Poor aqueous solubility	Requires effective wetting, particle-size control, or solubility enhancement
Hydrophobic active pharmaceutical ingredient	Can cause agglomeration and slow dissolution
High drug loading	Limits the amount of excipient available per tablet
Sensitivity to process variation	May create dissolution and bioequivalence failures
Chronic oncology use	Supports interest in lower pill burden and improved tolerability
Dose reductions in toxicity management	Makes multiple strengths or flexible dose delivery commercially useful

The reference product uses a conventional immediate-release tablet rather than a complex delivery system. This creates an opportunity for generic manufacturers to match the reference formulation efficiently, but it also limits the commercial value of minor excipient changes unless they improve manufacturing economics or patient use.

What excipient strategy is appropriate for a generic sorafenib tablet?

The lowest-risk strategy is a close qualitative and quantitative formulation match using standard pharmaceutical grades of microcrystalline cellulose, croscarmellose sodium, hypromellose, sodium lauryl sulfate, and magnesium stearate.

Recommended conventional formulation strategy

A generic manufacturer should prioritize:

1. Consistent wetting of sorafenib tosylate through controlled surfactant distribution.
2. Rapid and reproducible tablet disintegration.
3. Low lubricant sensitivity, because excess magnesium stearate can reduce wetting and dissolution.
4. Controlled granule or blend density to maintain tablet weight and content uniformity.
5. Low-moisture processing and packaging.
6. Film-coating compatibility without altering dissolution.
7. Tight control of particle-size distribution and API agglomeration.

Direct compression may reduce processing steps, but it can create segregation and flow problems if the API has poor flow or a broad particle-size distribution. Roller compaction or wet granulation can improve content uniformity and compactability, although wet processing introduces additional moisture and scale-up controls.

Excipient selection priorities

Excipient class	Preferred development objective
Diluent	Improve compactability without excessive tablet size
Disintegrant	Achieve rapid breakup while preserving mechanical strength
Surfactant	Increase wetting without creating stability or foaming problems
Binder	Prevent capping and friability during high-speed compression
Lubricant	Minimize ejection force while avoiding dissolution retardation
Film former	Protect tablet surface and deliver consistent appearance
Packaging system	Control moisture, light, and mechanical damage

A generic sponsor should avoid unnecessary excipient substitution when the reference product already provides a workable performance target. Regulatory authorities generally evaluate the finished product through pharmaceutical equivalence, bioequivalence, quality, and stability rather than through a requirement to copy every inactive ingredient.

What formulation technologies can improve sorafenib solubility?

Higher-value excipient opportunities involve increasing dissolution or reducing dose burden. The leading platforms are amorphous solid dispersions, nanocrystals, lipid-based formulations, cyclodextrin systems, and self-emulsifying drug delivery systems.

Amorphous solid dispersions

Polymers such as hypromellose acetate succinate, hydroxypropyl methylcellulose, and povidone can maintain sorafenib in a higher-energy amorphous state. Potential benefits include faster dissolution and improved apparent solubility.

The main risks are recrystallization, moisture sensitivity, polymer-driven viscosity, and manufacturing complexity. Spray drying or hot-melt extrusion may be suitable, but the process must establish physical stability across the intended shelf life.

Nanocrystal formulations

Wet milling or high-pressure homogenization can reduce sorafenib particle size and increase surface area. Stabilizers such as povidone, poloxamers, or surfactants may limit particle growth.

Nanocrystals can support smaller tablets or improved dissolution, but they create additional control requirements for particle-size distribution, aggregation, redispersibility, and residual processing materials.

Lipid-based systems

Self-emulsifying or self-microemulsifying systems can improve dispersion of hydrophobic sorafenib in gastrointestinal fluids. Candidate excipients may include medium-chain glycerides, nonionic surfactants, and cosolvents.

These systems may be valuable for liquid-filled capsules or enabling formulations. Their limitations include capsule compatibility, excipient tolerability, oxidation, leakage, and more complex stability programs.

Cyclodextrin and co-crystal approaches

Cyclodextrins can improve apparent solubility but may require substantial excipient quantities. Co-crystals and alternative solid forms may improve dissolution or physical stability, although they can raise new solid-state, patent, and regulatory questions.

What formulations are protected by sorafenib patents?

Sorafenib’s original pharmaceutical patent protection was directed primarily to the active compound and related chemical inventions rather than to a broad, durable platform of excipient claims. The original Bayer and Onyx intellectual-property portfolio covered substituted pyridine compounds, pharmaceutical compositions, and therapeutic uses. Core U.S. protection expired around the end of the 2020 period after applicable patent-term adjustment and pediatric considerations, enabling generic entry.[3,4]

The commercial significance is that a new excipient formulation cannot be assumed to be free of patent risk merely because the original active-ingredient patent has expired. A formulation developer must screen:

• Composition-of-matter patents.
• Salt and solid-form patents.
• Amorphous or crystalline form claims.
• Particle-size and nanocrystal claims.
• Pharmaceutical composition claims.
• Method-of-use claims.
• Manufacturing-process patents.
• Patents covering combination therapy or particular dosing schedules.

Patent status must be assessed by jurisdiction and claim scope. Orange Book listings are relevant to approved drug products and listed patents, but they do not capture every potentially relevant third-party patent or every non-listed formulation right.[3]

When did sorafenib lose exclusivity and when can generics launch?

Sorafenib lost practical U.S. market exclusivity after the expiration of the principal patent and regulatory exclusivity periods. The FDA has since approved generic sorafenib tablets, confirming that the reference product has been open to ANDA-based competition.[4,5]

Milestone	Commercial relevance
2005	FDA approval for advanced renal cell carcinoma
2007	FDA approval for unresectable hepatocellular carcinoma
2013	FDA approval for radioactive iodine-resistant differentiated thyroid cancer
Around 2020	Core U.S. patent protection ended, subject to patent-specific calculations
Post-2020	Generic tablet competition expanded

Exact launch rights can differ by applicant because of Paragraph IV certifications, first-filer status, 180-day exclusivity, litigation settlements, and product-specific approval timing. A manufacturer entering with a conventional tablet must conduct a current Orange Book and court-docket review rather than rely on the original Nexavar expiration date alone.

Are there Paragraph IV challenges to Nexavar?

Paragraph IV risk historically centered on patents listed for Nexavar in the FDA Orange Book. An ANDA applicant may certify that a listed patent is invalid, unenforceable, or will not be infringed. The certification can trigger patent litigation and a potential 30-month stay of approval under the Hatch-Waxman framework.[3,6]

For present commercial planning, the critical issue is less whether a historical challenge occurred and more whether any listed or unlisted patent remains capable of blocking the specific proposed product. A sponsor should distinguish:

• Historical litigation involving the original compound or use patents.
• Patent settlements that controlled the timing of generic entry.
• Current enforceable patents covering a formulation or manufacturing process.
• Patent rights that expired but remain visible in historical Orange Book records.

What is the FDA regulatory status of sorafenib generics?

Sorafenib generics are regulated as small-molecule drug products through the ANDA pathway. They must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug, comply with current good manufacturing practice requirements, and meet specifications for identity, strength, quality, purity, and stability.[5,7]

A conventional immediate-release tablet generally offers the clearest regulatory pathway. A formulation with materially different excipients may still be approvable, but the sponsor must control the effect of those excipients on dissolution, exposure, stability, and tolerability.

Excipient suppliers can create commercial value by offering:

• Compendial grades with strong lot-to-lot consistency.
• Low-peroxide or low-moisture polymers.
• Direct-compression grades.
• Co-processed excipients.
• Regulatory support files and global certificates.
• Proven performance in oncology solid-dose manufacturing.

Does sorafenib have biosimilar risk?

Sorafenib does not have biosimilar risk because it is a chemically synthesized small molecule, not a biologic. Competitive risk comes from generic tablets, authorized generics, regional branded products, alternative formulations, and therapeutic substitution within oncology.

The absence of biosimilar regulation does not eliminate formulation competition. A differentiated sorafenib product could compete through smaller tablets, easier swallowing, improved dissolution consistency, reduced pill burden, or an alternative administration route.

What commercial opportunities exist for sorafenib excipients?

The strongest opportunities are concentrated in generic manufacturing and enabling technologies rather than in a new excipient-based franchise around the original tablet.

Opportunity ranking

Opportunity	Technical risk	Commercial potential
Reference-like immediate-release tablet	Low	High for reliable generic supply
Lower-cost direct-compression process	Moderate	High if content uniformity is maintained
Improved disintegration and dissolution system	Moderate	Moderate
Amorphous solid dispersion	High	Moderate to high
Nanocrystal tablet or capsule	High	Moderate
Self-emulsifying lipid formulation	High	Selective
Pediatric or dysphagia-friendly dosage form	High	Niche
Combination product with another oncology agent	Very high	Potentially high but clinically and legally complex

Revenue exposure

Nexavar revenue has faced erosion from generic entry and competition across the oncology market. The value pool for excipient suppliers is therefore tied to aggregate generic volume, formulation development programs, manufacturing transfers, and regional launches rather than to continued exclusivity of the originator.

A supplier with a platform polymer or surfactant system may obtain more durable value by supporting multiple kinase inhibitors with similar solubility challenges. Sorafenib can function as a development reference product, but a single-product excipient strategy is unlikely to support substantial long-term pricing power once multiple generic manufacturers are established.

How strong is the patent estate for a new sorafenib formulation?

A new formulation can have meaningful patent value if it demonstrates a technically defined and commercially relevant advantage. The strongest claim categories may include:

• A specific amorphous dispersion with defined polymer and drug loading.
• A controlled particle-size distribution linked to dissolution performance.
• A stable lipid formulation with defined excipient ratios.
• A dosage form that reduces tablet burden or improves administration.
• A manufacturing process that produces a non-obvious solid form.
• A formulation with demonstrated exposure or food-effect advantages.

Weak patent positions typically rely on broad lists of conventional excipients, routine concentration ranges, or predictable substitutions without comparative performance data. Patent strength improves when the formulation has a narrow, reproducible composition and unexpected dissolution, stability, pharmacokinetic, or patient-use results.

What geographic coverage matters for sorafenib excipient products?

The United States, European Union, Japan, China, India, and major oncology markets should be evaluated separately. Patent expiry, generic approval, reference-product requirements, excipient acceptability, and local manufacturing economics differ by jurisdiction.

Excipient suppliers should maintain:

• United States Pharmacopeia and European Pharmacopoeia compliance where required.
• ICH stability data.
• DMF or equivalent regulatory support.
• Regional impurity and elemental-contaminant controls.
• Supply continuity for oncology products.
• Documentation for nitrosamines, residual solvents, and genotoxic impurities where applicable.

A formulation that is commercially efficient in the United States may not be optimal in India or China if local tablet tooling, excipient sourcing, packaging, or price controls differ.

What manufacturing and intellectual-property barriers remain?

The principal manufacturing barriers are not the basic tablet composition. They are API particle engineering, blend uniformity, dissolution reproducibility, scale-up, and stability.

The principal intellectual-property barriers are formulation-specific claims, solid-form rights, process patents, and method-of-use claims. A freedom-to-operate review should include national patent registers, the FDA Orange Book, WIPO records, European Patent Office records, and litigation databases. It should evaluate both active patents and abandoned or expired family members to identify claim history and prosecution limitations.

Key Takeaways

• Sorafenib is a poorly soluble small molecule supplied as a 200 mg immediate-release film-coated tablet.
• The reference formulation uses conventional excipients, including microcrystalline cellulose, croscarmellose sodium, hypromellose, sodium lauryl sulfate, and magnesium stearate.
• The lowest-risk commercial opportunity is a robust, reference-like generic tablet with reliable dissolution and low manufacturing cost.
• Higher-value formulation opportunities include amorphous solid dispersions, nanocrystals, lipid-based systems, and swallowability-focused dosage forms.
• Sorafenib has no biosimilar risk. Generic and formulation competition drive market erosion.
• Core U.S. patent protection ended around the 2020 period, but formulation, process, solid-form, and method-of-use patents require separate review.
• Excipient suppliers gain the strongest strategic position by supporting multiple poorly soluble kinase inhibitors rather than relying on sorafenib alone.
• New formulation patents are strongest when tied to defined compositions and demonstrated, unexpected performance advantages.

FAQs

What is the most important excipient for sorafenib dissolution?

Sodium lauryl sulfate is a key wetting agent in the reference formulation, but dissolution depends on the combined effect of API particle size, surfactant distribution, disintegrant performance, compression force, and lubrication.

Can sorafenib be formulated as an oral suspension?

Yes, an oral suspension is technically possible, but it requires control of particle size, sedimentation, redispersibility, dose uniformity, preservative strategy, and chemical stability. It would likely target patients with swallowing limitations rather than the broad generic market.

Is sorafenib suitable for hot-melt extrusion?

Sorafenib may be evaluated in hot-melt extrusion with an appropriate polymer system, but thermal stability, drug loading, residual crystallinity, and recrystallization must be demonstrated before the technology can support a commercial product.

Can excipient substitution avoid sorafenib patent infringement?

Not automatically. Changing excipients may avoid a narrow composition claim, but infringement analysis must also cover active-ingredient, solid-form, process, dosage-form, and method-of-use patents.

What is the best commercial route for a new sorafenib formulation?

For most sponsors, the best route is a conventional ANDA tablet with manufacturing-cost or dissolution advantages. A complex formulation is commercially attractive only if it produces a defensible clinical, adherence, dose-burden, or lifecycle-management benefit.

References

1. U.S. Food and Drug Administration. (2023). Nexavar (sorafenib tosylate) tablets: Prescribing information. FDA.

2. European Medicines Agency. (2006). Nexavar: EPAR product information. EMA.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

4. U.S. Patent and Trademark Office. (2024). Patent term adjustment and patent information for sorafenib-related U.S. patents. USPTO.

5. U.S. Food and Drug Administration. (2024). Drugs@FDA: Sorafenib tablet approvals. FDA.

6. U.S. Code. (2024). 21 U.S.C. § 355: New drugs and abbreviated new drug applications.

7. U.S. Food and Drug Administration. (2021). Guidance for industry: Bioequivalence studies with pharmacokinetic endpoints for drugs submitted under an ANDA. FDA.